Based on NIAGARA data, do you now feel more comfortable offering cisplatin based chemotherapy to patients with impaired renal function?

I agree, apart from the topline positive results in the intent-to-treat population, the preplanned subgroup analysis of lower GFR patients also appears to indicate a benefit, albeit somewhat less strong than traditional criteria. This adds to evidence from the phase 3 randomized VESPER trial of ddMV...